Head to Head Comparison: Nutra Pharma (OTCMKTS:NPHC) and Fortrea (NASDAQ:FTRE)

Nutra Pharma (OTCMKTS:NPHC) and Fortrea (NASDAQ:FTRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk & Volatility

Nutra Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500.

Valuation & Earnings

This table compares Nutra Pharma and Fortrea”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutra Pharma	$380,000.00	3.77	-$2.05 million	N/A	N/A
Fortrea	$2.72 billion	0.61	-$986.20 million	($4.91)	-3.59

Nutra Pharma has higher earnings, but lower revenue than Fortrea.

Profitability

This table compares Nutra Pharma and Fortrea’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nutra Pharma	-364.90%	N/A	-159.08%
Fortrea	-16.50%	9.51%	1.96%

Analyst Ratings

This is a breakdown of current ratings for Nutra Pharma and Fortrea, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutra Pharma	0	0	0	0	0.00
Fortrea	1	5	5	0	2.36

Fortrea has a consensus price target of $17.45, suggesting a potential downside of 1.13%. Given Fortrea’s stronger consensus rating and higher probable upside, analysts clearly believe Fortrea is more favorable than Nutra Pharma.

Summary

Fortrea beats Nutra Pharma on 8 of the 10 factors compared between the two stocks.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

About Fortrea

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.